13 June 2022

SkinBioTherapeutics plc

Share price movement

The Board of SkinBioTherapeutics plc (AIM: SBTX or the "Company") notes the recent share price movement and confirms that it is not aware of any material commercial or operational reason that might be the cause. 

The Company's position on sales of its first commercial product AxisBiotix-Ps® was outlined in the Interim Results dated 29 March 2022 where management acknowledged slower uptake than originally anticipated, and that it was not possible to predict the quantum impact on sales.

The team continues to focus on driving sales of AxisBiotix-Ps®. The marketing and advertising campaign is now very active, using influencers who have psoriasis themselves for the digital campaign and advertising in regional and national newspapers such as the Mail, Telegraph and Metro. The product continues to receive very positive customer feedback and the subscriber retention rate is now >80%.

Other pillars of the business, including work with Croda/Sederma are progressing accordingly to plan. 

As always, the Company will continue to inform the market should there be additional news flow.

-Ends-

For more information please contact:

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.

The Company is targeting a number of skin healthcare sectors, the most advanced of which are cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin axis. In each area SkinBioTherapeutics plans to exemplify its technology through human studies. The Company's first product, AsixBiotix-Ps™, a food supplement to address the symptoms of mild to moderate psoriasis was launched on 29 October - World Psoriasis Day.

The Company listed on AIM in April 2017 and is based in Manchester, UK. For more information, visit: www.skinbiotix.com.